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The steady increase in the number of health technologies and advances in associated research generate 
management challenges in the choice of technologies to be made available to the public. From 2011, 
the process of inclusion, exclusion and alteration of technologies to the Brazilian Unified Health 
System (SUS) has undergone major transformations, such as the creation of the National Committee 
on Technology Incorporation (CONITEC). This study analyzed the decisions of CONITEC since its 
inception until July 2015. The analyzed variables were: type of technology, reason for application, name 
of the technology, indication, claimant and CONITEC decision status. We found that the Government 
was the main claimant, accounting for 58.1% of the 420 cases. The most frequent request was inclusion 
(93.8%) and the technology type was medicine (61.4%). Of the incorporated medicines, the classes of 
antineoplastic/immunomodulatory were the most frequent (39.47%). Society’s desire for inclusion of an 
increasing amount of health technology contrasts with the limited resources available to management, 
which causes budget concerns. Using Health Technology Assessment (HTA), advances resulting from 
these innovations in the process were highlighted, and challenges were identified for the management 
and the academic community.
Uniterms: Brazilian Unified Health System/evaluation. Brazilian Unified Health System/technology. 
Health Technology Assessment. Health Technology. National Committee on Technology Incorporation/
Brazil.
INTRODUCTION
The steady increase in the number of health 
technologies available on the market and the advances in 
research have created management challenges regarding 
the choice of technologies to be made available to the 
population (Banta, Almeida, 2009). Health Technology 
Assessment (HTA) is a multidisciplinary field of public 
policy study that seeks to synthesize knowledge regarding 
clinical, social, ethical, environmental and economical 
implications of health technologies. A major goal of HTA 
is to guide decision-making by managers responsible 
for health policies, especially in regard to incorporating, 
excluding and modifying technologies available in a health 
system (Eddy, 2009).
Brazil has made official lists of the medicines to be 
provided by its public health system since 1964. These 
lists were initially updated by a public agency called 
“Drugs Central Office” (CEME) and, since 1975, they 
have been called the National List of Essential Medicines 
(RENAME), which currently is in its 9th modern edition, of 
2014, encompassing 840 items (Brasil, 2007). At first, this 
policy was more significantly related to Pharmaceutical 
Care, making little use of HTA knowledge. Requests for 
amendments of RENAME were referred to CEME, that 
took decisions guided only by general guidelines of the 
Ministry of Health and by standardized methodologies 
for drug analysis. There was not a defined frequency nor 
even a time frame for the list to be reviewed (Brasil, 2007).
The first steps towards institutionalizing the 
process though wich technologies are incorporated by 
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federal health management only took place in 2006, 
with the creation of the Commission for Incorporation of 
Technologies (CITEC), a public agency of the Brazillian 
Ministry of Health (MH). In 2008, CITEC joined the 
Secretariat of Science, Technology and Strategic Inputs 
(SCTIE) (Novaes, Elias, 2013).
From 2006 to 2011, CITEC received 351 proposals 
for incorporation, exclusion or alteration of health 
technologies, incorporating 85 technologies, not 
incorporating 65, excluding eight, not excluding two, 
filing four requests, extinguishing seven for being outside 
its scope and, also, preparing and reviewing 95 clinical 
protocols and therapeutic guidelines (Silva, Petramale, 
Elias, 2012).
With the increasing pressure on managers of Brazil’s 
public Unified Health System (SUS) to incorporate new 
technologies through actions of representatives of the 
pharmaceutical industry, patients, prescribers, medical 
companies, carriers and disease associations, as well 
as through judicialization of health issues, there was 
an escalation on the discussion of how to balance the 
guarantee of access to technology – as a step towards 
accomplishing the goal of universal health coverage – with 
its rational use and, also, with the sustainability of the 
system in the face of increasingly high costs (Capucho et 
al., 2012). The debate culminated when a public hearing 
was held by the Supreme Court in 2009, from which 
came several contributions accepted by the government, 
resulting in legislative changes in 2011 (Brasil, 2008; 
DECIT, 2011).
The new laws and regulations turned the processes 
of evaluation and incorporation of technologies to SUS 
into a state policy (Brasil, 2011a); replaced CITEC by the 
newly created SUS’ National Technology Incorporation 
Comission (CONITEC); and changed the management 
model on the coverage of technologies by SUS, 
establishing the need to start an administrative proceeding 
to each demand of inclusion, exclusion and modification 
of health technology to the system (Brasil, 1999; Brasil, 
2011a). CONITEC was given the responsability to conduct 
those proceedings based on scientific evidence, especially 
of HTA, on legal principles and on public management 
standarts. The result of the proceedings may reflect in the 
amendment of SUS’ lists: the National List of Actions and 
Health Services (RENASES) and the RENAME. This, in 
turn, may modify SUS’ coverage and consequently the 
effective delivery of actions, services, medications and 
procedures available for the population’s health care. 
Therefore, the changes affect directly not only the users 
and the managers of SUS, but also all the pharmaceutical 
and healthcare industry in general.
Understanding that these institutional and legislative 
innovations set a new framework of HTA in Brazil, with 
repercussions, since 2012, on the course and result of 
the process of incorporation, exclusion and modification 
of technologies made available by Brazilian public 
health system and hence their availability to the assisted 
population, this study aimed to analyze the demands 
submitted to CONITEC, during a period of three 
years since its creation, and to examine the possible 
improvements of this new framework over previous 
models adopted by the country.
MATERIAL AND METHODS
This is a descriptive study, with a quantitative 
approach of the demands submitted to CONITEC for 
inclusion, exclusion and alteration of technologies to 
SUS, based on official data from the Brazilian Ministry 
of Health, from January 2012 to July 2015.
The data was collected through document analysis, 
by research from secondary sources, more specifically 
in the databases available for consultation from the 
MH’s websites, namely: 1) application forms of the 
inclusion, exclusion and alteration technologies to SUS; 
2) classification and categorization reports of the 
demands submitted to CONITEC; 3) individualized 
reports containing the foundations, decisions and 
recommendations regarding the demands evaluated by 
the CONITEC; 4) contributions and public consultations 
forms, relating to demands for the inclusion, exclusion and 
alteration technologies to SUS and, 5) ordinances of the 
Secretariat of Science, Technology and Strategic Inputs of 
the Ministry of Health (SCTIE/MH), with the publication 
of the decisions in these processes.
For this study, the collected information in the 
databases of the Ministry of Health were as follows: a) 
type of technology (medicines, procedures, products 
and protocols); b) type of request (inclusion, exclusion, 
expansion of use, preparation and review); c) name of the 
technology; d) indication; e) claimant (public entities, 
pharmaceutical and private entities linked to organized 
civil society) and; f) CONITEC decision status (regarding 
the inclusion, exclusion and alterations of technologies 
at SUS).
Regarding the status of the application, the processes 
that had a CONITEC decision on the merits of the 
application were considered ‘complete’, as well as those 
that were closed by formal issues (status of “demand 
already incorporated into SUS”, “proposal rejected for 
not being in formal compliance with documentation”, 
“processes closed at the request of the claimants, and 
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“demands outside CONITEC scope”). The completed ones 
that did not meet the cases closed by formal issues were 
also classified according to the criteria of the Ministry of 
Health, “included”, “not included” and “exclusion”. On 
the other hand, demands considered unfinished, fell under 
the following status according to the MH: “under review”, 
“documentation under compliance analysis”, “under review 
after public consultation”, “pending final assessment for 
publication” and “in the public consultation phase”.
Among the types of technology, specific variables 
for medicines were established, compiling information 
regarding the indication of the incorporated medicines 
and the reasons for deciding not to include them. The 
incorporated medicines were classified according to the 
first and fifth ATC (Anatomical Therapeutic Chemical) 
levels.
We also collected information on the publishing of 
public consultations performed during the study period, 
observing the number of demands in progress and the 
number of completed consultations, with and without the 
contribution of society in general.
The collected data were stored and analyzed using 
Microsoft Office Excel 2013. The results were expressed 
as absolute and relative frequencies. Some variables were 
stratified by the type of claimant.
The research was authorized and approved by the 
Ethics and Research Committee of Ana Nery’s Nursing 
School (CAAE: 07972412.3.0000.5238).
RESULTS
During the study period, 420 proposals were sent 
to CONITEC, with 394 (93.8%) related to the inclusion, 
21 (5.0%) were exclusion requests, and five (1.2%), were 
related to alteration requests (three for the expansion 
of technologies use and two for the review of Clinical 
Protocols and Therapeutic Guidelines-PCDT).
Public entities were the largest request claimants 
(58.1%), followed by companies and laboratories 
(35.7%), and private non-profit associations (6.2%) 
(Table I). Among the requests submitted by public entities, 
only 2.4% (10 requests) were provocations by judicial 
authorities, with the rest (55,7%) coming from the public 
authorities within the Ministry of Health structure, the 
Union, the States or the Cities. Medicines were the type of 
technology that resulted in the greatest number of requests 
among claimants (61.4%).
Of the 420 requests submitted to CONITEC, 85.5% 
were classified as completed and 14.5% were still in some 
stage of the review process by CONITEC. In turn, of the 
359 already completed, 137 (38.2%) were accepted for 
inclusion of technology, 72 (20.1%) were not incorporated 
and 18 cases (5.0%) were for the exclusion of RENASES 
and RENAME technology. Seventy-two (20.1%) cases 
were rejected due to problems with the documentation. In 
one case, the extinction occurred because the demand had 
already been incorporated into SUS before the application, 
while in 52 (14.5%) cases, the proceeding was terminated 
at the request of the applicants themselves before the 
evaluation.
Table II shows the relationship between the 
claimants and the status of the decision or step the 
assessment of CONITEC was in, by type of technology. 
Regarding demands related to the government and which 
relate to medicines (n=133), 39.1% of applications 
were incorporated and 11.3% were not incorporated. 
Regarding the Pharmaceutical Industry (n=109), 16.5% 
of applications were incorporated, 40.4% were not 
incorporated, and 30.3% were refused for non-compliance 
of formal documentation; regarding the case of private 
non-profit associations (n=16), 37.6% of applications 
were incorporated and 50% had the proposal rejected by 
non- compliance of formal documentation.
Regarding forwarded procedures related to 
the government (n=83), 61.4% of applications were 
incorporated. In the case of private associations (n=6), 
83.3% were refused for non-compliance to formal 
documentation and 16.7% are in some stage of analysis. 
The Pharmaceutical Industry (n=7) had 57,1% of 
its procedure’s applications refused for the same 
TABLE I - Types of technology distribution according to the claimant qualifications. January 2012 - July 2015, Brazil
Claimant/Types of 
technology
Government n (%) Pharmaceutical 
Industry n (%)
Private Association 
n (%)
TOTAL n (%)
Medicine 133 (54.5) 109 (72.7) 16 (61.5) 258 (61,4)
Procedure 83 (34) 7 (4.7) 6 (23.1) 96 (22,8)
Product 26 (10.7) 32 (21.3) 4 (15.4) 62 (14,8)
Protocol 2 (0.8) 2 (1.3) - 4 (0,9)
TOTAL 244 (58.1) 150 (35.7) 26 (6.2) 420 (100)
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reason of non-compliance to formal documentation. 
Regarding products, of the applications sent by the 
government (n=26), 34.6% were incorporated. As for the 
pharmaceutical industry, 59.4% had proposals rejected 
by non-compliance to formal documentation. The 
applications of private associations (n=4) had only one 
request incorporated and another refused. Requests sent 
by the government and the pharmaceutical industry that 
involved protocols were all dismissed according to the 
claimant’s own request.
Table III shows a list of incorporated medicines 
and their indications to the RENAME list. Of the 258 
incorporation demands, submitted to CONITEC, 76 were 
approved, resulting in the incorporation of 50 different 
medicines and seven immunization products, being 
all organized under the first and fifth level of the ATC 
classification. Of the approved requests, 39.5% were for 
antineoplastic/immunomodulatory medicines and 28.9% 
were for anti-infective for systemic use. 
Table IV shows the reasons of CONITEC for the 
non-incorporation of 59 medicines to SUS. Each medicine 
application could be rejected for more than one reason, 
adding up to 120 reasons used in the non-incorporation 
decisions. In 25% of applications, the medicine was not 
included due to the fact the studies presented limited 
results of efficacy and/or safety of the medicine in question 
or failed to establish clinical benefit. In 18.3%, the 
economic analysis was considered limited and the budget 
impact analysis seemed underestimated with estimates 
uncertainties generated by cost-effective analysis.
As for the results of civil society participation 
with the public appointments made by the CONITEC, 
120 public consultations were performed using forms 
published by the MH in the Union’s Official Gazette. Of 
this total, four were still current, while 116 were already 
concluded. Of the total of completed consultations, 106 
received contributions from society.
DISCUSSION
Our findings show the extent of the process of 
inclusion, exclusion and alteration of technologies to 
SUS. CONITEC had a high demand for incorporation of 
new technologies, especially medicines. These demands 
come mainly from the public sector, which was the only 
sector that submitted requests to exclude repeated and 
inefficient technologies and to expand the use of medicines 
already incorporated. The Commission decided in 38.2% 
of inclusion requests in favor of the incorporation of the 
technology into SUS. Another important result concerns 
the significant participation of civil society in public 
consultations.
Evaluating the variable of the claimants of the process, 
we found the importance and the volume of public entities 
participating in this process, since the RENASES and the 
RENAME compositions directly influence the public health 
administration, not only at a federal level, but also state- and 
city-wise. Among the claimants classified as public entities, 
the Public Prosecutor’s Office and the Ministry of Justice 
accounted for only ten demands in CONITEC.
The small number of cases initiated at the instigation 
of these judicial entities does not conclusively demonstrate 
the absence of interference or reduce the problem of 
judicialization of the SUS’ technology inclusion process, 
TABLE II - Request claimant distribution and status of the National Committee on Technology Incorporation (CONITEC), according 
to types of technology. January 2012 - July 2015, Brazil
Claimants/CONITEC 
decision status
Government n (%) Pharmaceutical Industry n (%) Private Associations n (%)
M PC PD PT M PC PD PT M PC PD PT
Incorporated 52 (39.1) 51 (61.4) 9 (34.6) - 18 (16.5) - - - 6 (37.6) - 1 (25) -
Non-incorporated 15 (11.3) 4 (4.8) 1 (3.8) - 44 (40.4) - 7 (21.9) - - - 1 (25) -
Excluded 16 (12.1) 2 (2.4) - - - - - - - - - -
Under analysis* 12 (9.0) 2 (2.4) 7 (27.0) - 8 (7.3) 1 (14.3) 2 (6.2) - 1 (6.2) 1 (16.7) - -
Refused proposals** - 1 (1.2) 1 (4.2) - 33 (30.3) 4 (57.1) 19 (59.4) - 8 (50.0) 5 (83.3) 1 (25) -
Closed according to 
claimant’s request
28 (21.0) 6 (7.2) 7 (4.2) 2 (100) 5 (4.6) 1 (14.3) - 2 (100) 1 (6.2) - - -
Others*** 10 (7.5) 17 (20.6) 1 (8.3) - 1 (0.9) 1 (14.3) 4 (12.5) - - - 1 (25) -
TOTAL 133 83 26 2 109 7 32 2 16 6 4  -
M=Medicine; PC=Procedure; PD=Product; PT=Protocol. * under analysis; under review for compliance analysis; under review after public 
consultation. ** proposal refused for non-conformity of formal documentation. *** demand already incorporated into SUS; demand outside the 
CONITEC scope; pending final assessment for publication; in the public consultation phase.
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TABLE III - List of medicines incorporated by CONITEC with the respective 5th level ATC classification and its indications to the 
National List of Essential Medicines (RENAME). January 2012 - July 2015, Brazil
Incorporated medicines * ATC Classification ** Indications of Incorporate Medicines defined by claimants’ protocols
Abatacepte L04AA24 Moderate to severe rheumatoid arthritis
Abatacepte L04AA24 Rheumatoid arthritis
Abatacepte L04AA24 Rheumatoid arthritis
Lanreotida acetate H01CB03 Acromegaly
Adalimumab L04AB04 Rheumatoid arthritis
Alfa interferon L03AB11/L03AB10 Adjuvant chemotherapy of cutaneous melanoma in clinical 
stage III
Alfataliglicerase A16AB11 Gaucher Disease
Ambrisentan C02KX02 Pulmonary Arterial Hypertension (PAH)
Azathioprine L04AX01 Rheumatoid arthritis
Azithromycin pill 250 mg J01FA10 Whooping cough
Beclomethasone R03BA01 Chronic obstructive pulmonary disease-COPD
Biotin A11HA05 Biotinidase deficiency
Boceprevir J05AE12 Hepatitis C
Boceprevir J05AE12 Hepatitis C (Infection with genotype 1 chronic hepatitis C virus)
Bosentan C02KX01 Pulmonary Arterial Hypertension (PAH)
Budesonide R03BA02 Chronic obstructive pulmonary disease-COPD
Certolizumab pegol L04AB05 Rheumatoid arthritis
Hydrocortisone cypionate 10 mg D07AC Congenital adrenal hyperplasia, newborns diagnosed in the 
National Program for Neonatal Screening-PNTN
Hydrocortisone cypionate 20 mg D07AC Congenital adrenal hyperplasia, newborns diagnosed in the 
National Program for Neonatal Screening-PNTN
Clobetasol D07AD01 Topical psoriasis
Chloramphenicol suspension J01BA01 Spotted Fever
Erlotinib hydrochloride L01XE03 Advanced non-small cell lung or metastatic cancer
Clozapine N05AH02 Affective Bipolar Disorder
Darunavir 600 mg J05AE10 Antiretroviral therapy for HIV patients
Doxycycline injectable J01AA02 Spotted Fever
Etanercept L04AB01 Rheumatoid arthritis
Fenoterol R03CC04 Chronic obstructive pulmonary disease-COPD
Fingolimode L04AA27 3rd line treatment of Multiple Sclerosis
Formoterol R03AC13 Chronic obstructive pulmonary disease-COPD
Gefitinib L01XE02 Lung cancer
Golimumab L04AB06 Rheumatoid arthritis
Hydroxyurea L01XX05 Sickle cell disease
Adjuvant hormone therapy to external 
beam radiation therapy (LHRH analog 
goserelin and cyproterone)
L02AE03 Prostate cancer
Prior hormone therapy to external 
beam radiation therapy (LHRH analog 
goserelin and cyproterone)
L02AE03 Prostate cancer
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Incorporated medicines * ATC Classification ** Indications of Incorporate Medicines defined by claimants’ protocols
Infliximab L04AB02 Rheumatoid arthritis
Lamotrigine N03AX09 Affective Bipolar Disorder
Maraviroc J05AX09 Adult patients previously treated and infected with HIV-1 virus
Maraviroc J05AX09 Treatment of adult patients previously treated and infected with 
HIV-1 virus
Imatinib mesylate L01XE01 Hypereosinophilic syndrome – SHE
Imatinib mesylate L01XE01 Adjuvant Chemotherapy, gastrointestinal stromal tumor
Methotrexate injection L01BA01 Ankylosing spondylitis
Methotrexate injection L04AX03 Psoriasis
Naproxen M01AE02 Rheumatoid arthritis
Naproxen M01AE02 Psoriatic arthritis
Naproxen M02AA12 Ankylosing spondylitis
Olanzapine N05AH03 Affective Bipolar Disorder
Palivizumab J06BB16 Prevention of infection by respiratory syncytial virus
Penicillin J01C Prevention of Congenital Syphilis
Penicillin oral J01C Sickle cell disease in children
Quetiapine N05AH04 Affective Bipolar Disorder
Raltegravir J05AX08 Antiretroviral therapy for HIV patients
Risperidone N05AX08 Child’s autism
Risperidone N05AX08 Affective Bipolar Disorder
Rituximab L01XC02 Follicular lymphoma
Rituximab L01XC02 Rheumatoid arthritis
Rituximab L01XC02 Rheumatoid arthritis
Salbutamol R03AC02 Chronic obstructive pulmonary disease-COPD
Salmeterol R03AC12 Chronic obstructive pulmonary disease-COPD
Sildenafil G04BE03 Systemic sclerosis
Tacrolimus L04AD02 Primary Nephrotic syndrome 
Thalidomide L04AX02 Myelodysplastic syndrome
Telaprevir J05AE11 Hepatitis C (genotype 1 infection Chronically by the hepatitis 
C virus)
Tocilizumab L04AC07 Rheumatoid arthritis
Tocilizumab L04AC07 Rheumatoid arthritis
Trastuzumab L04AC07 Early breast cancer
Trastuzumab L01XC03 Advanced breast cancer
Trastuzumab L04AC07 Early breast cancer
Influenza vaccine J07BB03 Chronic obstructive pulmonary disease-COPD
Vaccine Adsorbed diphtheria, tetanus 
and pertussis
J07CA06 Vaccinating Pregnant Women
Vaccine Adsorbed Hepatitis A (inactive) J07BC02 Active immunization
HPV vaccine J07BM02 Prevention of cervical cancer
TABLE III - List of medicines incorporated by CONITEC with the respective 5th level ATC classification and its indications to the 
National List of Essential Medicines (RENAME). January 2012 - July 2015, Brazil (cont.)
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Incorporated medicines * ATC Classification ** Indications of Incorporate Medicines defined by claimants’ protocols
HPV vaccine J07BM02 Prevention of cervical cancer
Vaccine for measles, rubella, mumps 
and chicken pox.
J07BD54 Active immunization
Vacine Tdap-R J07AM51 Booster vaccination against diphtheria, tetanus and whooping 
cough, in individuals over four years.
HPV vaccine J07BM01 Prevention of cervical cancer and diseases related to HPV 
6,11,16 and 18
Tetraviral vaccine (measles, mumps, 
rubella and chickenpox)
J07BD54 Measles, mumps, rubella and chickenpox
* The same medicine may appear on the table related to the same ATC classification for three reasons: 1) multiple demands for 
different indications or uses of the same medicine; 2) multiple demands of the same medicine for the same indication, but in 
different presentations (dosages) and 3) repetition of the same demand for the same indication by different claimants. ** ATC = 
Anatomical Therapeutic Chemical
TABLE III - List of medicines incorporated by CONITEC with the respective 5th level ATC classification and its indications to the 
National List of Essential Medicines (RENAME). January 2012 - July 2015, Brazil (cont.)
TABLE IV - Distribution of reasons for non-incorporation of medicines requested. January 2012 - July 2015, Brazil
Reasons for non-incorporation of medicines Absolute Frequency (n) Percentage (%)
Studies showed limited results of efficacy and/or safety of the medicine in question or 
do not establish clinical benefit
30 25.0
The limited economic analysis and budget impact analysis are presented with 
underestimated uncertainties of estimates generated by cost-effective analysis
22 18.3
Available scientific evidence does not prove the superiority of these medicine s from 
the medicinal product already available on SUS, and the results of economic analysis 
(sensitivity analysis) showed higher cost and lower effectiveness
19 15.8
Lack of studies on the effects of long-term use of the medicine and assessment of 
associated adverse events. 15 12.5
Low methodological quality of the studies and characteristics of questionable selection 
criteria 10 8.4
Average duration of clinical and/or size of the sample for evaluation of medicine efficacy 
for the treatment of specific disease are insufficient
9 7.5
Presented studies were not robust enough (lack of evidence) to prove the effect of its 
use in the proposed scenario 7 5.8
Ideal dose has not been established 5 4.2
Considerable incidence of adverse events 3 2.5
Total 120 100
because this number reflects only those cases in which 
these bodies provoked CONITEC to perform the inclusion 
analysis.
This provocation can occur prior to the filing 
of a lawsuit, in a previous procedure of a civil action 
instruction, for example; or already in the course of action 
when the judiciary body understands that it is not entitled 
to such an incorporation decision, because it presents a 
highly technical character. In cases, however, that the 
incorporation of the demand has been previously denied 
by CONITEC and is forwarded to the Judiciary, through 
class actions, another option that has been happening is the 
emission of court orders that lead to the modification of 
SUS technologies lists, without following technical HTA 
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criteria (Guimarães, 2014). Once there is, in such cases, 
judicial decision with res judicata requiring the inclusion 
of a medicine, CONITEC, at first, may not go against it for 
technical reasons. Beyond these actions, judicialization is 
still a very pulverized phenomenon, with individual actions 
and lawsuits, seeking the provision of certain technologies 
for a single individual claimant without the technology 
being added to the lists of SUS (Grinover et al., 2014).
Among the completed processes, the incorporation 
decisions correspond numerically to a little less than 
double the non-incorporation decisions. The high rate 
of non-incorporation for merit grounds coincides with 
the fact that Decree No. 7,646/2011 began to demand a 
more rigorous, technical evaluation, by the emission of 
a report by the plenary of the CONITEC, in which the 
following elements will be examined: scientific evidence 
on the efficiency, accuracy, effectiveness and safety of the 
medicine, product or procedure at the center of the process; 
comparative economic evaluation of benefits and costs 
in relation to already embedded technologies; the impact 
the inclusion of technology to SUS will have (CONITEC, 
2015). On the other hand, this amount of inclusion 
decisions is also an important finding and proves that the 
Ministry of Health and the CONITEC are recognizing the 
need to complement the RENASES and the RENAME, 
offering new health technologies more efficient than those 
already available to the population.
The ordinary increase in the number of produced and 
embedded technologies can be understood in the light of 
the increase in the volume of knowledge and information 
produced on medical technologies (Cutler, Macclellan, 
2001; Lichtenberg, 2001). These, in turn, favor immediate 
care, diagnostic accuracy, and provide more security to the 
whole multidisciplinary team and also bring other benefits 
to public health in general. In Brazil, the health sector is 
the largest component of all scientific and technological 
production, thus generating the necessary incentive for 
new fundamental technology breakthroughs to improve 
quality of life for the population and promote the healing 
of diseases (Brasil, 2008).
Not surprisingly, the bulk of inclusion requests are 
for medicines, since research and innovation related to 
this type of technology also dominate the market and the 
scientific community (Brasil, 2011c). The CONITEC’s 
claimants, therefore, desire to complement RENASES 
with further actions and health services available to the 
population, as well as RENAME with further drugs, which 
becomes evident by the predominance of requests for 
inclusion of new technologies, in particular the inclusion 
of antineoplastic/immunomodulatory medications and 
anti-infective medicines for systemic use.
The reasons for the high frequency of antineoplastic/
immunomodulatory medicines may be related: 1) the high 
cost of treatment with these medicines, involving cutting-
edge and high complexity technologies affecting not only 
social classes that usually use SUS, but also patients from 
medium or even higher classes; 2) the determinations 
of the National Policy of Oncology Care (Vianna et al., 
2005) and the goals established by the Ministry of Health’s 
Strategic Plan 2011-2015, which led to the organization of 
the Ministry of Health and the Health Departments of the 
States and Cities to promote, coordinate and implement 
strategic projects of technological resources using cost-
effectiveness, efficacy and quality studies and technology 
assessment of cancer care in Brazil (Kligerman, 2000; 
Brasil, 2005) and, 3) the high levels of judicialization 
demands, seeking the coverage of these medicines, 
especially Rituximab and Trastuzumab, with high costs to 
the public budget (Portal da Justiça Federal, 2015).
The antineoplastic medicines are an exception to 
RENAME (as are the ophthalmologic and those used 
in emergency procedures) because they have a different 
system of supply and their financing comes from High 
Complexity Procedure Authorizations (APAC). The 
only antineoplastic medicines that are provided directly 
by SUS are Thalidomide, Trastuzumab and Imatinib 
Mesylate. Antineoplastic drugs are not included on a 
list, but on chemotherapeutic procedures registered on 
APAC’s forms in the System of Outpatient Information 
of SUS. Only hospitals authorized by the Health Ministry 
to perform oncology procedures may supply and use 
these medicines. The payment follows a list of codes 
registered on APAC’s forms. The hospitals are responsible 
for the acquisition and supply of these types of drugs and 
are refunded monthly after presenting the codes to the 
Health’s Secretary. It’s worth mentioning, however, that 
the HPV vaccine and Thalidomide are listed on the 9th 
edition of RENAME, as are Tocilizumabe, Rituximabe, 
Muromonabe, Natalizumabe, Infliximabe, Golimumabe, 
Daclizumabe, Certolizumbae Pegol, Basiliximabe and 
Adalimumabe (Brasil, 2013b). 
The inclusion of those medicines, which use had 
already been constantly granted by the courts, allows the 
management to acquire them on a large scale and through 
a bidding process, which reduces the cost to the health 
budget. The high incorporation of anti-infective medicines, 
on the other hand, may be related to bacterial resistance. 
Systemic use of these medicines leads to increasing 
resistance of microorganisms to products already available 
at SUS. The high consumption of an antimicrobial species 
may, therefore, result in the development of bacterial 
resistance, creating the need for the incorporation to SUS 
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of new medicines for the treatment of resistant organisms 
(Dias, Monteiro, Menezes, 2010).
The results also demonstrate a social clamor for 
compliance with the principle of integrality of SUS’ 
coverage. The fact is that public health investment in 
Brazil is still far from ideal. According to the 2012 
statistics of the World Health Organization (WHO), Brazil, 
among the countries with universal public service models, 
has the lowest state participation in health financing. Of 
the entirety of the federal budget, only 4.7% of public 
expenditure was allocated to health in 2001, a percentage 
that increased to 8.7% in 2014, but is still below the world 
average (11.7%) and even the African countries average 
(10.6%). Not only does the country lack priority to health 
in terms of budget allocation, but also in terms of Gross 
Domestic Product (GDP) percentage and, especially, a 
control over expenditures, when, in reality, we see that 
many resources available for health are spent on other 
areas by the management (World Health Statistics, 2015). 
It is important, therefore, to track how public 
administrators distribute the limited budget resources of 
SUS between a growing number of technologies, thus 
preventing the constant expansion of coverage from leading 
to scarcity of resources, hampering access. In other words, 
an increasingly comprehensive coverage will mean little, 
with an increasing number of technologies theoretically 
available to the public, if, in reality, these technologies 
cannot be made available due to lack of resources.
Although numerically not very significant, the 
requests for expansion of the medicine’s use are also 
reflexes of the progress in medicine research, indicating the 
discovery of new therapeutic uses for existing medicines 
on the market. Expanding the usage and indications would 
extend SUS coverage because it gives health professional 
a new alternative treatment based on already available and 
accessible technology in SUS.
The study also shows that many of the requests 
were rejected due to non-compliance of the forwarded 
formal documentation, especially from the pharmaceutical 
industry. This result is attributed to the fact that there were 
alterations in the CITEC procedure, in which there was 
no requirement documents for the protocol of procedures 
in favor of the CONITEC process, which in turn created 
a minimum list of necessary documentation for the 
demands to pass from the preliminary examination by 
the Executive Secretariat to the plenary commission; as 
well as the standards adaptation period for submitting 
demands by the industry in this new reality (DECIT, 
2011; CONITEC, 2015). The only application in which 
the demand was unnecessary because the technology had 
already been included by the RENASES and RENAME 
before the application came from a civil association. 
Considering the above, it is essential that these institutions 
have better assistance and specific information about 
the new CONITEC procedures, thus ensuring effective 
participation in these processes, representing organized 
civil society. Moreover, this measure will avoid wasted 
CONITEC resources, by assessing unnecessary demands.
Analyzing the volume of rejected decisions for 
non-conformity of documentation makes it clear that the 
reforms in the regulation process since 2011 were positive, 
with the creation of a terminative decision, dissociated 
from the analysis of request merit, for those cases of formal 
divergence or lack of documents in the application. The 
trend over these first three years is that the more the public 
knows about this relationship and the more experienced 
and knowledgeable those interested parties are, the fewer 
cases of rejection will occur by non-compliance of formal 
documentation, thus making the process more efficient 
and transparent. 
This innovation, along with the establishment of a 
period for a CONITEC decision (180 days), which did 
not occur in the previous system, made the process most 
expeditious and efficient, making it possible to verify a 
significant increase in the number of decisions issued 
by CONITEC compared with CITEC. While this one 
presented decisions for 224 processes between 2006 
and 2011 (Silva, Petramale, Elias, 2012), that one has 
already completed 359 demands from 2012 to July 2015 
(CONITEC, 2015).
On the other hand, the non-incorporation of certain 
medicines due to merit rejection by the CONITEC is a 
consequence of the more strict criteria required by the 
new legislation, related to the investigation of the clinical, 
economic and social consequences of the technologies use 
as HTA process, which result in the refusal of inclusion 
requests due to a technical basis, generating a real 
administrative jurisprudence and CONITEC technique, 
which allows for transparent and objective knowledge 
by the interested parties, by the Ministry of Justice and 
the general public of the technical criteria used by the 
committee.
Advertising these decisions also depends upon 
the private press, with the TV news and other media 
responsible for the wide and swift dissemination of the 
new technologies included in SUS, which will be available 
to the public, so that people know their rights to obtain 
access to these technologies, and can demand respect for 
the 180 days period, provided for in Article 25 of Decree 
No. 7,646/2011 (Brasil, 2011b).
Civil society showed a great interest in participating 
in these public consultations, provided in art. 19 of Decree 
L. M. N. Nunes, M. M. F. Fonteles, A. C. B. Passos, P. S. D. Arrais
Braz. J. Pharm. Sci. 2017;53(2):e16073Page 10 / 12
No. 7,646/2011, which made the evaluation process more 
democratic and pluralistic (Brasil, 2011b).; Delduque, 
Dallari, Alves, 2014.). Thus, the comparison of documents 
submitted for public consultation with the fundamentals of 
CONITEC’s decisions may have contributed in assisting 
final decisions in the processes of inclusion, exclusion or 
alterations of technologies to SUS.
CONCLUSION
Since 2011, with the creation of CONITEC 
and with the important innovations in the Brazilian 
legislation regarding this process, there was a substantial 
improvement of the HTA management tools in the 
country. Changes such as public consultations as a 
mandatory step, made the process more democratic 
and the possibility of dismissal of the case by formal 
inconsistency made the committee analysis of the 
documentation more prompt.
Three years of requests submitted to CONITEC 
were analyzed and we found that the public entities 
were the largest claimants, followed by companies and 
laboratories, and finally, private non-profit associations, 
which are responsible for a small number of applications.
Regarding those medicines rejected for inclusion in 
CONITEC, we found that the main reasons these results 
were negative was the fact that the medicine studies in 
question had limited efficacy and/or safety results or failed 
to establish clinical benefits.
A trend became evident, regarding the inclusion 
of anticancer/immunomodulatory and anti-infective 
medicines for systemic use, which has been shown 
according to surveys and recent publications on the growth 
of these medicines.
The data collected also led to the conclusion 
that almost all of the cases to date sought only to add 
technologies to SUS, generating a budget concern about 
the possibility of providing these technologies to the 
population. This reality reinforces the criticism of low 
public investment to health in the country, due to the 
lack of priority for this sector, and highlights the health 
manager’s challenge in balancing the increasing demand 
with the reality of insufficient State resources.
The process of inclusion, exclusion and alteration 
of technologies to SUS needs to be constantly monitored, 
with data collection, processing and categorization of 
the demands submitted to CONITEC, to compare the 
empirical results of the processes with the expectations and 
plans of management, as well as the concerns of service 
users and programmatic nature studies in the HTA area.
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